Decision Resources

Decision Resources Group offers best-in-class, high-value information, analysis and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on this analysis and data to make informed decisions that are critical to their success.

Post-ACA Implementation Brings Opportunity and Uncertainty to Pharmaceutical Companies Looking to Capture Growth in New Places

May 8, 2013

ACO and Exchange Information is the Most Critical to Understand in the next Six Months, According to Decision Resources Group
More

New Executive Briefing: A new, convoluted paradigm emerges as increased consolidations lead to stricter antitrust review

March 5, 2013

Healthcare consolidations are on the rise, as industry stakeholders anticipate the Jan. 1, 2014, launch of several healthcare reform initiatives. With the increase in mergers and acquisitions activity has come more stringent and effective antitrust review from the Federal Trade Commission.
More

Decision Resources Product Manager, Roy Moore, quoted in Specialty Pharmacy Times

December 20, 2012

Clinical Pathways May Factor into ACO Reimbursement Strategies
The adoption of clinical pathways in oncology has the potential to streamline care. Breast cancer, colorectal cancer, and non-small-cell lung cancer appear to be the conditions that are the current priorities for pathway programs, according to a new report from Decision Resources entitled, “Impact of Payer-Imposed Strategies on Market Access in Oncology: Clinical Pathways, Accountable Care Organization Contracting, Specialty Pharmacy, and the Evolution of the Buy and Bill Model.”

More